ImmunityBio settles IP lawsuit with HCW, acquires TGFb trap assets and licenses

ImmunityBio, Inc.

Settlement resolves arbitration and federal lawsuit with HCW Biologics; no monetary consideration from ImmunityBio.
ImmunityBio receives ownership of IP and drug candidates HCW9218, HCW9219, HCW9209 for TGFb-related fusion proteins.
HCW9218 is a bifunctional fusion protein (TGFb trap + IL-15) studied in Phase 1/1b trials for ovarian and pancreatic cancer.
ImmunityBio also gets exclusive license to use TF Platform for oncology targets PDL-1, IL-7, IL-12, IL-18, IL-21, plus one more.
Parties exchange mutual releases; ImmunityBio to dismiss arbitration after compliance with settlement terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.